我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

A Brief Overview of the Pharmacokinetics of Esomeprazole

Andersson Hassan-Alin

Esomeprazole is a proton pump inhibitor commonly prescribed for the treatment of gastrointestinal disorders such as gastro esophageal reflux disease, peptic ulcers, and Zollinger-Ellison syndrome. Understanding the pharmacokinetics of esomeprazole is crucial for optimizing its therapeutic efficacy and minimizing potential adverse effects. After oral administration, esomeprazole is rapidly absorbed from the gastrointestinal tract, with a bioavailability of approximately 50-68% due to first-pass metabolism in the liver. The drug is extensively bound to plasma proteins, primarily albumin, and has a relatively high volume of distribution, indicating good tissue penetration. Esomeprazole is primarily metabolized in the liver by cytochrome P450 enzymes, namely CYP2C19 and CYP3A4, resulting in the formation of inactive metabolites.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。